Our Team

Our name encompasses our mission: to create a new class of therapeutics that inhibit NOD-like receptors — specifically the NLRP3 inflammasome, which is an intracellular multi-protein complex that assembles in response to environmental danger signals and plays a key role in the regulation of innate immunity.

We are pursuing this mission at a time of growing awareness about the revolutionary potential of the NLRP3 inflammasome. Supported by blue-chip investors and led by a management team with a proven track record in drug discovery, NodThera is pushing the science of NLRP3 inflammasome inhibition into new frontiers.

Leadership

Adam
Alan
Allison
Chris
Mark
nick

Board

Investors